Loss of CD19 expression in B-cell neoplasms

Noraidah Masir, T. Marafioti, M. Jones, Y. Natkunam, T. Rüdiger, M. L. Hansmann, D. Y. Mason

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Aims: To investigate whether an antibody against an intracellular epitope can detect CD19 in routine biopsy specimens and thus to document in detail its expression in human lymphomas. Method and results: A polyclonal antibody to the C terminus of CD19 was used to immunostain paraffin-embedded samples of normal and neoplastic lymphoid tissues. CD19 was widely expressed in normal B cells and in extramedullary plasma cells. It was found in most B-cell neoplasms, but expression in follicular lymphoma was weak (33/69) or negative (four cases). Similarly, CD19 expression in diffuse large B-cell lymphomas was weak (28/56) or negative (eight cases). In T-cell-rich B-cell lymphomas, CD19 was also weak (4/10) or negative (three cases). CD19 was often absent in post-transplant B lymphoproliferative disease, classical Hodgkin's disease and plasma cell neoplasms. An unexpected finding was the frequent absence of CD19 in the neoplastic cells in lymphocyte predominant Hodgkin's disease. Conclusions: CD19 can now be detected in routine biopsy specimens. In contrast to the classical pan-B marker CD20, CD19 is not always strongly expressed in B-cell neoplasms. Furthermore, the lymphocytic and histiocytic (L&H) cells of lymphocyte predominant Hodgkin's disease (which express most B-cell-associated markers) commonly lack CD19.

Original languageEnglish
Pages (from-to)239-246
Number of pages8
JournalHistopathology
Volume48
Issue number3
DOIs
Publication statusPublished - Feb 2006
Externally publishedYes

Fingerprint

B-Lymphocytes
Hodgkin Disease
Neoplasms
Plasma Cell Neoplasms
Lymphocytes
Biopsy
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Antibodies
B-Cell Lymphoma
Lymphoid Tissue
Plasma Cells
Paraffin
Epitopes
Lymphoma
T-Lymphocytes
Transplants

Keywords

  • B-cell neoplasms
  • CD19
  • Expression
  • Immunohistochemistry

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Masir, N., Marafioti, T., Jones, M., Natkunam, Y., Rüdiger, T., Hansmann, M. L., & Mason, D. Y. (2006). Loss of CD19 expression in B-cell neoplasms. Histopathology, 48(3), 239-246. https://doi.org/10.1111/j.1365-2559.2005.02317.x

Loss of CD19 expression in B-cell neoplasms. / Masir, Noraidah; Marafioti, T.; Jones, M.; Natkunam, Y.; Rüdiger, T.; Hansmann, M. L.; Mason, D. Y.

In: Histopathology, Vol. 48, No. 3, 02.2006, p. 239-246.

Research output: Contribution to journalArticle

Masir, N, Marafioti, T, Jones, M, Natkunam, Y, Rüdiger, T, Hansmann, ML & Mason, DY 2006, 'Loss of CD19 expression in B-cell neoplasms', Histopathology, vol. 48, no. 3, pp. 239-246. https://doi.org/10.1111/j.1365-2559.2005.02317.x
Masir N, Marafioti T, Jones M, Natkunam Y, Rüdiger T, Hansmann ML et al. Loss of CD19 expression in B-cell neoplasms. Histopathology. 2006 Feb;48(3):239-246. https://doi.org/10.1111/j.1365-2559.2005.02317.x
Masir, Noraidah ; Marafioti, T. ; Jones, M. ; Natkunam, Y. ; Rüdiger, T. ; Hansmann, M. L. ; Mason, D. Y. / Loss of CD19 expression in B-cell neoplasms. In: Histopathology. 2006 ; Vol. 48, No. 3. pp. 239-246.
@article{03297ec91f294a57a14f4814a63ce263,
title = "Loss of CD19 expression in B-cell neoplasms",
abstract = "Aims: To investigate whether an antibody against an intracellular epitope can detect CD19 in routine biopsy specimens and thus to document in detail its expression in human lymphomas. Method and results: A polyclonal antibody to the C terminus of CD19 was used to immunostain paraffin-embedded samples of normal and neoplastic lymphoid tissues. CD19 was widely expressed in normal B cells and in extramedullary plasma cells. It was found in most B-cell neoplasms, but expression in follicular lymphoma was weak (33/69) or negative (four cases). Similarly, CD19 expression in diffuse large B-cell lymphomas was weak (28/56) or negative (eight cases). In T-cell-rich B-cell lymphomas, CD19 was also weak (4/10) or negative (three cases). CD19 was often absent in post-transplant B lymphoproliferative disease, classical Hodgkin's disease and plasma cell neoplasms. An unexpected finding was the frequent absence of CD19 in the neoplastic cells in lymphocyte predominant Hodgkin's disease. Conclusions: CD19 can now be detected in routine biopsy specimens. In contrast to the classical pan-B marker CD20, CD19 is not always strongly expressed in B-cell neoplasms. Furthermore, the lymphocytic and histiocytic (L&H) cells of lymphocyte predominant Hodgkin's disease (which express most B-cell-associated markers) commonly lack CD19.",
keywords = "B-cell neoplasms, CD19, Expression, Immunohistochemistry",
author = "Noraidah Masir and T. Marafioti and M. Jones and Y. Natkunam and T. R{\"u}diger and Hansmann, {M. L.} and Mason, {D. Y.}",
year = "2006",
month = "2",
doi = "10.1111/j.1365-2559.2005.02317.x",
language = "English",
volume = "48",
pages = "239--246",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Loss of CD19 expression in B-cell neoplasms

AU - Masir, Noraidah

AU - Marafioti, T.

AU - Jones, M.

AU - Natkunam, Y.

AU - Rüdiger, T.

AU - Hansmann, M. L.

AU - Mason, D. Y.

PY - 2006/2

Y1 - 2006/2

N2 - Aims: To investigate whether an antibody against an intracellular epitope can detect CD19 in routine biopsy specimens and thus to document in detail its expression in human lymphomas. Method and results: A polyclonal antibody to the C terminus of CD19 was used to immunostain paraffin-embedded samples of normal and neoplastic lymphoid tissues. CD19 was widely expressed in normal B cells and in extramedullary plasma cells. It was found in most B-cell neoplasms, but expression in follicular lymphoma was weak (33/69) or negative (four cases). Similarly, CD19 expression in diffuse large B-cell lymphomas was weak (28/56) or negative (eight cases). In T-cell-rich B-cell lymphomas, CD19 was also weak (4/10) or negative (three cases). CD19 was often absent in post-transplant B lymphoproliferative disease, classical Hodgkin's disease and plasma cell neoplasms. An unexpected finding was the frequent absence of CD19 in the neoplastic cells in lymphocyte predominant Hodgkin's disease. Conclusions: CD19 can now be detected in routine biopsy specimens. In contrast to the classical pan-B marker CD20, CD19 is not always strongly expressed in B-cell neoplasms. Furthermore, the lymphocytic and histiocytic (L&H) cells of lymphocyte predominant Hodgkin's disease (which express most B-cell-associated markers) commonly lack CD19.

AB - Aims: To investigate whether an antibody against an intracellular epitope can detect CD19 in routine biopsy specimens and thus to document in detail its expression in human lymphomas. Method and results: A polyclonal antibody to the C terminus of CD19 was used to immunostain paraffin-embedded samples of normal and neoplastic lymphoid tissues. CD19 was widely expressed in normal B cells and in extramedullary plasma cells. It was found in most B-cell neoplasms, but expression in follicular lymphoma was weak (33/69) or negative (four cases). Similarly, CD19 expression in diffuse large B-cell lymphomas was weak (28/56) or negative (eight cases). In T-cell-rich B-cell lymphomas, CD19 was also weak (4/10) or negative (three cases). CD19 was often absent in post-transplant B lymphoproliferative disease, classical Hodgkin's disease and plasma cell neoplasms. An unexpected finding was the frequent absence of CD19 in the neoplastic cells in lymphocyte predominant Hodgkin's disease. Conclusions: CD19 can now be detected in routine biopsy specimens. In contrast to the classical pan-B marker CD20, CD19 is not always strongly expressed in B-cell neoplasms. Furthermore, the lymphocytic and histiocytic (L&H) cells of lymphocyte predominant Hodgkin's disease (which express most B-cell-associated markers) commonly lack CD19.

KW - B-cell neoplasms

KW - CD19

KW - Expression

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=33644987359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644987359&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2005.02317.x

DO - 10.1111/j.1365-2559.2005.02317.x

M3 - Article

VL - 48

SP - 239

EP - 246

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 3

ER -